Antibodies have created high expectations for effective yet tolerated therapeutics in acute
myeloid leukemia (AML). Hitherto the most exploited target is CD33, a myeloid differentiation …

Introduction Treatment of acute myeloid leukemia (AML) has changed dramatically in the
past ten years with the approval of targeted agents, the first of which was the anti-CD33 …

Background: Gemtuzumab ozogamicin consists of a semisynthetic derivative of
calicheamicin, a potent cytotoxic antibiotic, linked to a humanized anti-CD33 monoclonal …

In September 2017, the US FDA announced re-approval of gemtuzumab ozogamicin (GO), a
CD33-targeting immunoconjugate, for treatment of newly diagnosed and relapsed/refractory …

Introduction: Gemtuzumab ozogamicin (GO) is a combination of calicheamicin and a
recombinant humanized IgG4 antibody directed against CD33. From 2000 to 2010, it was …

Simple Summary Gemtuzumab Ozogamicin (GO) is a drug approved for the treatment of
acute myeloid leukemia (AML). It targets leukemic cells that express the CD33 molecule on …

Through the years gemtuzumab ozogamicin (GO) has moved from a panacea in the
treatment of acute myeloid leukemia (AML) to a pariah and back again. Early promise of …

Abstract Purpose of Review The advent of several targeted agents has revolutionized the
treatment of acute myeloid leukemia (AML) in recent times; however, majority of patients are …

CD33 is expressed by acute myeloid leukemia (AML) cells in> 80% of patients but not by
normal hematopoietic stem cells, suggesting that elimination of CD33+ cells may be …

Despite recent advances in the treatment of acute myeloid leukemia (AML), relapses remain
high, and long-term survival is poor, emphasizing the need for better treatment options …